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A New Class of Phytoestrogens:
Evaluation of the Estrogenic
Activity of Deoxybenzoins
regulator of transcription. Two subtypes of ER have
been described, ER and ER, and reported to exhibit
overlapping but distinct tissue distribution patterns and
to differ in their ligand binding ability and transcription
activation properties [3, 4]. Some phytoestrogens have
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Deoxybenzoins, intermediates in the synthesis ofSummary
isoflavones, are found in several plant and marine
sources [10, 11]. Plants with known estrogenic activityAlthough deoxybenzoins are intermediates in the syn-
thesis of isoflavones, their estrogenic activity has not in their extracts, such as Glycyrrhiza sp. [12] Trifolium
subterraneum [13] and Ononis spinosa, are good sourcesbeen investigated. Eleven deoxybenzoins were syn-
thesized and their estrogenicity was evaluated. While of natural deoxybenzoins. Although the estrogenic activ-
ities of Glycyrrhiza sp. and Trifolium sp. have been attrib-their affinities for estrogen receptors (ER) ER and
ER were found grossly comparable to those of daid- uted mainly to isoflavones [14], their structural similari-
ties with deoxybenzoins led us to study the estrogeniczein, some exhibited considerable selectivity and tran-
scriptional bias toward ER, which appeared to allow activity of the latter. Here, we report on the synthesis
and the estrogenic activity of 11 (among them threefor enhancement of ER-mediated transcription via
deoxybenzoin binding of ER. Their activity to stimu- new) deoxybenzoins and discuss the structural determi-
nants of their interaction with ER.late the proliferation of ER-positive breast cancer cells
and regulate the expression of endogenous and stably
transfected reporter genes differed considerably, with
Results and Discussionsome inhibiting cell proliferation while effectively in-
ducing gene expression at the same time. Molecular
Chemical Synthesismodeling confirmed that deoxybenzoins fit well in the
Using a method previously described by Wahala et al.ligand binding pocket of ER, albeit with different ori-
[11], a number of deoxybenzoins were synthesized.entations. Our data support the view that deoxyben-
Starting from the appropriately substituted phenols andzoins constitute a promising new class of ER-biased
phenylacetic acids, a Friedel-Crafts reaction catalyzedphytoestrogens.
by boron trifluoride takes place (Figure 1A). Among the
dihydric phenols, resorcinol and substituted resorcinolsIntroduction
react with variously substituted phenylacetic acids, giv-
ing excellent yields of deoxybenzoins. In contrast, theEstrogens of plant origin (phytoestrogens) are known to
trihydric phenol phloroglucinol gave good yield by re-affect the physiology of the female reproductive system
acting with p-methoxy-phenylacetic acid but not with(uterus, ovaries, breast), the cardiovascular system, the
p-hydroxy-phenylacetic acid, despite that different con-brain, and the skeleton. Consequently, there is growing
ditions were tested. For this reason, compound 4 wasinterest in using phytoestrogens and synthetic deriva-
obtained by the demethylation of compound 3 usingtives thereof for the prevention of several diseases, in-
boron tribromide [15] in dichloromethane at 70C. Including breast and prostate cancer, postmenopausal
the reactions of p-hydroxy-phenylacetic acid with resor-osteoporosis, and cardiovascular diseases [1, 2]. Phy-
cinols, minor byproducts with an ethoxy group in the 4toestrogens are believed to exert their physiological ef-
position were detected. It is known [16] that ethyl fluo-fects via the estrogen receptor (ER), a ligand-activated
ride is produced from the complex of boron trifluoride
with ethyl ether, which can react with the hydroxyl group*Correspondence: mnalexis@eie.gr (M.N.A.), skaltsounis@pharm.
uoa.gr (A.-L.S.) of p-hydroxy-phenylacetic acid. In the case of 4-cloro-
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Deoxybenzoin Activation of Transcription via ER
and/or ER
To discern how deoxybenzoins affect ER and ER tran-
scriptional activity, we transfected HEK-293 human em-
bryonic carcinoma cells with an expression vector for
human ER or ER as well as a luciferase reporter en-
dowed with a consensus estrogen-responsive element
(ERE) and the core thymidine kinase (tk) promoter. Using
0.1–0.4 g of ER expression vector and 1 nM estradiol,
we observed maximum reporter responses amounting
to 16.3 0.5- and 10.8 0.9-fold in the presence of ER
and ER, respectively. However, because ER exhibited
higher constitutive transcriptional activity than ER, hor-
monal inductions were 5.3  0.4- (ER) and 5.8  0.3-
fold (ER). By comparison, using 2 at 10 M, at which
concentration all estrogenic deoxybenzoins exhibit
maximum proliferative response (see Figure 3B), induc-
tions were 6.1  0.1- (ER) and 9.2  0.2-fold (ER)
(Figure 2A), indicating a more effective recruitment of
coactivators to the tk promoter by deoxybenzoin bind-
ing of ER. Thus, ER-mediated deoxybenzoin induc-
tion of the response is higher than the ER-mediated
one and, in addition, exceeds that of the hormone signifi-
cantly (ANOVA, p  0.01). The IC50 values for ER- and
ER-mediated inductions by 2 of a response equal to
that of the hormone were 421 and 66 nM, respectively.
This 6.4-fold difference in potency exceeds the ER
binding selectivity of 2 by1.2-fold, implying again that
deoxybenzoin binding may render ERmore capable of
recruiting transcriptional coactivators to the tk promoter
than ER. Table 1 (columns 5 and 6) compares reporter
inductions at 10 M deoxybenzoin to those at 10 M
daidzein and 1 nM estradiol in the presence of either
ER or ER. Only 2 exhibited higher reporter responsesFigure 1. Synthesis of Deoxybenzoins and Daidzein
than estradiol. Interestingly, several deozybenzoins,(A) Synthesis of deoxybenzoins 1–11.
(B) Synthesis of daidzein. whether ER selective or not, exhibited a bias toward
ER-mediated transcription at 10 M, with 1, 4, 5, 7, 9,
and 11 apparently being the most biased. Table 1 shows
further that daidzein binding of ER and ER providedresorcinol, compound 9 was obtained in yield of 12%.
for somewhat higher reporter responses than 2, albeitIsoflavone daidzein (12) was obtained by the cyclization
slightly less biased.of the corresponding deoxybenzoin (2) using boron tri-
In light of the above, we wondered whether the ERfluoride as catalyst (Figure 1B) [11].
binding selectivity and transcriptional bias of 2 affects
reporter responses in the presence of both ER. We co-
Relative Binding Affinities for ER and ER transfected HEK-293 cells with ER (0.1 g) and ER
Deoxybenzoin binding of ER and ER was studied us- (0.1 or 0.2 g) expression vectors, keeping vector
ing fluorescence polarization (FP) to determine the con- amounts well below the limit (0.5 g) we have observed
centration (IC50) required for 50% inhibition of ES2 (fluo- squelching effects to come about with these cells, and
rescent ER ligand) binding to commercial receptor exposed transfectants to 30 and 100 nM 2, concentra-
preparations [17]. The relative binding affinity (RBA) val- tions that provide for ER-mediated inductions of 3.0-
ues of deoxybenzoins for ER (RBA) thus determined and 4.5-fold, but ER-mediated inductions of 1.3- and
were comparable to that of the isoflavone daidzein (12) 2.1-fold, respectively (Figure 2A). We observed that 100
(Table 1). By contrast, RBA values varied considerably, M 2 elicited a significantly higher (ANOVA, p  0.01)
with that of 2 in particular being 15-fold higher than reporter response in the presence of ER and ER than
those of daidzein and the natural deoxybenzoin ononetin either receptor alone (Figure 2B). By contrast, ER had
(1). Notably, 2 exhibited by far the highest selectivity for no effect on the marginal ER-mediated response at 30
ER; 5, 6, 10, and 11 were moderately ER-selective; nM 2, implying that an activation of either ER that could
1, 3, 4, 8, 9, and daidzein exhibited a moderate bias provide for a sizeable pool of heterodimers is likely nec-
toward ER; and only 7 was unbiased. Inspection of the essary before positive modulation by 2 becomes appar-
structures of Figure 1 reveals that ER selectivity is ent. Interestingly, the presence of ER dampened the
associated with R1, R2, R3 	 H and R4 	 OH, F, or NO2 ER-mediated response to 1 nM estadiol, indicating a
(2, 5, 6), and that it may reflect a better accommodation lower transcriptional activation of the tk promoter by
both ER as compared to ER alone in the presence ofof Br bulkiness (10, 11).
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Table 1. Comparison of Relative Binding Affinities and Transcriptional Activities of Deoxybenzoins 1–11 to Those of Daidzein and
Estradiol
Compound RBAa RBAa RBSb TAc TAc
Estradiol 100 100 5.30 5.81
1 0.0209  0.0018 0.0157  0.0016 0.75 2.89 5.59
2 0.0506  0.0036 0.2734  0.0264 5.40 6.08 9.15
3 0.0189  0.0032 0.0075  0.0004 0.40 ND ND
4 0.0522  0.0046 0.0280  0.0027 0.54 1.59 3.22
5 0.0220  0.0027 0.0276  0.0022 1.25 2.82 5.29
6 0.0367  0.0029 0.0517  0.0040 1.41 2.05 2.91
7 0.0109  0.0016 0.0107  0.0011 0.98 3.31 6.66
8 0.0697  0.0051 0.0341  0.0042 0.49 1.37 1.43
9 0.0087  0.0014 0.0033  0.0002 0.38 1.63 3.05
10 0.0022  0.0003 0.0036  0.0001 1.64 ND ND
11 0.0556  0.0085 0.0906  0.0085 1.63 2.45 5.04
Daidzein 0.0309  0.0029 0.0199  0.0014 0.64 7.60 10.47
ND, not determined.
a RBA values for ER (RBA) and ER (RBA) are mean SEM of at least three independent experiments, with those of 17-estradiol arbitrarily
set equal to 100.
b Relative ER binding selectivity (RBS) is calculated by [RBA]/[RBA].
c Transcriptional activities in the presence of ER (TA) or ER (TA) are calculated by the following: [reporter response in the presence of
ER and 10 M test compound]/[reporter response in the presence of ER and in the absence of test compound]. The TA and TA values of
1 nM 17-estradiol are given for comparison.
the hormone. Notably, the experiment of Figure 2C levels of estrogen for binding to the native ER and ER,
respectively. Thus, the use of 2 for hormone replacementshows that normalizing deoxybenzoin responses to the
therapy (HRT) may be envisaged.respective vehicle responses rather than to the activity
In the absence of hormone, 0.1–10 M 2 stimulatedof reporter alone also results in a higher response with
the proliferation of MCF-7 cells significantly, but 100 Mboth receptors than with either receptor alone, exclud-
2 inhibited proliferation (Figure 3B), in accordance withing that changes in ER constitutive activity might ac-
reports that high concentrations of phytoestrogens im-count for the enhancement of deoxybenzoin activation
pact ER-independent growth-inhibitory effects [22]. Byof the response upon coexpression of ER and ER.
contrast, the proliferation of MDA-MB-231 cells in theFigure 2C shows, in addition, that changes in ER consti-
presence of 10 M 2 was not significantly higher thantutive activity(ies) might not account for the decreasing
basal proliferation in its absence, implying that deoxy-of the estradiol response either, further suggesting that
benzoin stimulation of MCF-7 cell proliferation likely de-ER heterodimerization is responsible for the opposite
pends on ER. All deoxybenzoins but 10 and 11 exhib-modulator effects of estradiol and 2. With several deoxy-
ited a similar profile of proliferative response. Table 2benzoins exhibiting an ER binding selectivity and a
shows that the effective concentration (EC25) of deoxy-bias toward ER-mediated transcription comparable to
benzoin stimulation of proliferation to a level equal to2 (Table 1), the inference is that they too could positively
25% that of 0.1 nM estradiol varied from 0.02 to 
10modulate ER transcriptional activity via ER.
M (column 2), and that the efficacy of the response at
10 M deoxybenzoin was high to moderate (i.e.,  ofStimulation of Cell Proliferation
25% that of 0.1 nM estradiol) with 1–4 and 7–9 and weakStimulation of proliferation of breast cancer cells by
(i.e., 10%–25% that of 0.1 nM estradiol) with 5 and 6,estrogens is believed to depend primarily on ER [18].
whereas 10 and 11 inhibited rather than stimulated pro-
In light of this, deoxybenzoin stimulation of the prolifera-
liferation (column 4). Inspection of the structures of Fig-
tion of MCF-7 breast cancer cells, known to express ure 1 reveals that stimulation of proliferation is associ-
much higher amounts of ER than ER, was compared ated with R4 	 OH, whether derivatized or not. Weto that of MDA-MB-231 breast cancer cells, which are wondered whether RBA or RBA of 1–4 and 7–9 corre-
ER negative [19, 20]. Estradiol stimulation of MCF-7 lated with their proliferative potencies. While 2, 4, and
cell proliferation attained maximum value (288% that of 8 have RBA values of 0.05, 2 binds ER with 10-
hormone-free cells) by 0.1 nM hormone, in accordance fold higher affinity and is 300 times more potent than
with reports that the complement of estradiol binding either 4 or 8, indicating that ER binding of 2 likely
sites of MCF-7 cells is fully occupied by hormone enhances its proliferative potency. Similarly, 1 and 3
concentrations 0.1 nM [21]. We found that IC50 values have RBA values of 0.02, but 1 binds ER with
for 50% inhibition of 0.3 nM [3H]estradiol binding to 2-fold higher affinity and is5 times more potent than
MCF-7 cells by increasing concentrations of radioinert 3. A similar comparison of 7 and 9 further supports the
estradiol, 2, and daidzein are 0.41  0.04, 405  59, notion of a dependence of the proliferative potency of
and 1717 177 nM, respectively, matching RBA values deoxybenzoins on their binding of ER. Significantly, it
as determined using FP. We also found that whole-cell has been reported that estrogen stimulation of MCF-7
hormone binding is fully competed at 0.003, 3, and 10M, cell proliferation involves activation of src kinase as well
respectively (Figure 3A), suggesting that 0.1 and 1 M of as transcription of cell cycle genes by ER and ER
[23–26].2 can effectively compete (50%) with postmenopausal
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Activation of Reporter Gene Expression
To elaborate on the transcription activation potencies
and efficacies of the synthesized deoxybenzoins, we
used MCF-7 cells (clone D5L) stably transfected with
an ERE-dependent luciferase reporter endowed with a
strong (-globin) promoter [27]. Estradiol stimulation of
reporter expression attained maximum level (351% that
of hormone-free cells) by 0.1 nM hormone. Table 2
shows that the effective concentration (EC50) of deoxy-
benzoin stimulation of luciferase expression to a level
equal to 50% that of 0.1 nM estradiol varied from 0.06
to 
10 M (column 5) and that the efficacy of the re-
sponse at 10 M deoxybenzoin was high to moderate
with 1, 2, 5–8, and 11 and weak with 3, 4, 9, and 10
(Table 2, column 7 and Figure 3C). It is currently unclear
whether the 10-fold higher EC50 for activation of
ER-mediated reporter response to 2 in HEK-293 cells
(Figure 2A) as compared to that in MCF-7 cells reflects
modulation of ER activity by ER rather than the inher-
ent difficulty of transfected ER to replicate hormonal
events as staged by endogenous ER. The high constitu-
tive activity of transfected ER points to the latter alterna-
tive as being more likely. By comparison, 1, 2, 7, and 8
stimulate gene expression as well as MCF-7 cell prolifer-
ation; 3, 4, and 9 stimulate proliferation more than gene
expression; 5, 6, and 11 stimulate gene expression more
than proliferation; and 10 stimulates neither. Thus, unlike
cell proliferation, F, NO2, or H substitution for 4-OH is
not detrimental to gene expression, indicative of differ-
ent determinants guiding deoxybenzoin stimulation of
these responses. Notably, the correlation between in-
duction efficacies at 10 M deoxybenzoin and the TA
values of Table 1 (r 	 0.812, p 	 0.008) gets stronger
when 2 is excluded (r 	 0.889, p 	 0.003), and the trend
is maintained when the second most ER-selective and
transcriptionally biased deoxybenzoin (11) is excluded
also (r 	 0.901, p 	 0.006), which may be taken to
suggest that ER binding selectivity and transcriptional
bias of 2 and 11 interfere with ER being the sole deter-
minant of the gene expression response in their
presence.
ER-mediated activation of transcription from ERE-
dependent promoters depends on two transcription ac-
tivation functions (AF), AF1 and AF2 [3]. While the AF2
of ER and ER are of similarly high strength, AF1 of
ER is much more potent than ER, resulting in a higher
activation of transcription from ERE-dependent promot-
ers [26]. We have shown above that the ER-dependent
reporter response to 2 is positively modulated by ER;
the opposite is true for the response to estradiol. Pet-
tersson et al. [28] have reported that ER exercised a
similar modulation of their reporter responses to estra-Figure 2. Deoxybenzoin Regulation of ER- and/or ER-Mediated
diol and genistein, a phytoestrogen of much higher se-Gene Expression
lectivity for ER (RBA	 43.9, RBS	 51) than 2. Since(A) Induction by 2 of ER and ER transcriptional activity. HEK-293
ER and ER colocalize in nuclear clusters housingcells were transfected with an ERE-luciferase reporter and plasmids
expressing human ER (solid circles) or ER (open circles) and chromatin remodeling components [29], they could form
incubated with vehicle, estradiol, or increasing concentrations of 2.
Normalized levels of luciferase activity were expressed relative to
those of transfected cells treated only with vehicle (set to 1). The
levels of luciferase activity induced by 1 nM estradiol in cells ex- luciferase reporter and plasmids expressing human ER and/or ER
pressing ER (dashed line) or ER (dotted line) are shown for com- and incubated with estradiol or 2, as indicated. Normalized levels
parison. of luciferase activity were expressed relative to those of cells trans-
(B and C) Coexpression of ER and ER enhances the transcrip- fected with the reporter alone and treated with vehicle (set to 1, [B])
tional efficacy of 2. HEK-293 cells were transfected with the ERE- or of transfected cells treated only with vehicle (set to 1, [C]).
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transcriptionally active heterodimers. These could sen-
sitize the AF-1-mediated activation of the gene expres-
sion program of MCF-7 cells to the presence of ER-
selective and transcriptionally biased deoxybenzoins.
Induction of Alkaline Phosphatase Activity
To ensure that activity is not restricted to breast cancer
cells, we tested deoxybenzoin estrogenicities using Ishi-
kawa endometrial adenocarcinoma cells. It has been
reported that hormonal induction of alkaline phospha-
tase (AlkP) activity in these cells is estrogen specific,
with androgens, progestins, glucocorticoids, and miner-
alocorticoids exhibiting negligible activity [30], and that
induction by phytoestrogens is an indicator of the intrin-
sic estrogenic activity of these compounds [31]. As al-
ready observed with the other responses, estradiol stim-
ulation of AlkP expression attained maximum level
(414% that of hormone-free cells) by 0.1 nM hormone.
Table 2 shows that the effective concentration (EC25) of
deoxybenzoin stimulation of AlkP expression to a level
equal to 25% that of 0.1 nM estradiol varied from 0.06
to 
10 M (column 8), and that the efficacy of the re-
sponse at 10 M deoxybenzoin was high to moderate
with 1, 2, 5, 7, and 11 and weak or marginal with 3, 4,
6, and 8–10 (column 10). In fact, 1, 2 and 7 stimulate
AlkP expression as well as MCF-7 cell proliferation; 3,
4, 8, and 9 stimulate proliferation more than AlkP expres-
sion; 5 and 11 stimulate AlkP expression but either fail
to stimulate proliferation (5) or inhibit it (11); and 6 and
10 stimulate neither. Thus, deoxybenzoins that potently
transactivate the luciferase reporter [rank order of po-
tencies (2
 1  5 7 6  11)] stimulate AlkP expres-
sion as well (2 
 5  7  1  11). Yet, 5 and 11 cannot
stimulate the proliferation of breast cancer cells, which
makes them a potentially safe choice for HRT.
We next looked for structural features that could ac-
count for the differences in activity described above.
Whether gene-transactivation or cell-proliferation wise,
substitutions in positions R1 and R2 lead to a decrease
in both RBA and estrogenic activity (compare 7 with
R1 	 Cl and 4 with R2 	 OH to 2 with R1 	 H and R2 	
H). The presence of 4-OH is associated with higher
proliferative activity as well as RBA (compare 5 with
R4 	 F to 2 with R4 	 OH). However, derivatization of
4-OH lowers both RBA and estrogenic activity (compare
1 to 2, 3 to 4, and 7 to 9), and this is also the case
following exchange of 4-OH for larger substitutes (com-
pare 10 and 6 to 2). In fact, 10 seems to be totally inactive
in all three assays (Table 2). Interestingly, substitution
of F (but not Br) for 4-OH produced a deoxybenzoin (5)
Figure 3. Biological Responses versus Deoxybenzoin Binding of relatively active with respect to gene expression but
Native ER proliferatively inert, whereas presence of 3-Br in con-
(A) Displacement of tritiated estradiol from the native ER of intact junction with lack of 4-OH produced a deoxybenzoin
MCF-7 cells by increasing concentrations of radioinert estradiol, 2,
(11) somewhat less potent than 5 gene-expression wise,and daidzein, as indicated
yet clearly inhibitory cell-proliferation wise.(B) Percent stimulation of the basal (estrogen-free) proliferation of
MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) cells in the
presence of increasing concentrations of 2, as obtained using the
Models of Deoxybenzoin Binding of ERMTT assay.
Conformational Analysis(C) Induction of luciferase expression in MCF-7:D5L cells using in-
Hormonal activity of steroidal and nonsteroidal estro-creasing concentrations of 1–11, as indicated.
gens is associated with H bonding ability of hydroxyl
groups mimicking the 3-OH and the 17-OH of estradiol,
an O-O distance between these groups in the range
Chemistry & Biology
402
Table 2. Biological Responses to the Deoxybenzoins 1–11, Daidzein, and Estradiol
MCF-7 Proliferation Reporter Gene Expression Alkaline Phosphatase Activity
Relative Relative Relative
Compound EC25a (M) Potencyb Efficacyc EC25a (M) Potencyb Efficacyc EC25a (M) Potencyb Efficacyc
1 0.91  0.05 0.0007 197  7 3.42  0.17 0.0008 407 47 3.83  0.71 0.0005 179 16
2 0.02  0.01 0.0399 413 14 0.06  0.01 0.0461 443 49 0.06  0.01 0.0331 319 51
3 4.96  1.40 0.0001 178  4 
10 0.0003 130 23 
10 0.0002 116 17
4 4.94  1.39 0.0001 186  7 
10 0.0003 157 12 
10 0.0002 141 17
5 
10 0.0001 129  3 3.62  1.16 0.0008 367 60 2.13  0.86 0.0009 225 16
6 
10 0.0001 123 11 8.54  0.86 0.0003 298 37 8.25  1.75 0.0002 157 10
7 1.06  0.47 0.0006 258  5 5.33  1.05 0.0005 353 46 2.46  0.22 0.0008 249 18
8 6.75  2.40 0.0001 166 10 
10 0.0003 194  9 
10 0.0002 116  8
9 6.19  3.14 0.0001 170 12 
10 0.0003 146 32 
10 0.0002 132  6
10 NA 95  7 
10 0.0003 139 58 7.51  0.95 0.0002 104 12
11 NA 75  9 9.52  0.39 0.0003 260 45 5.32  1.80 0.0004 180 18
Daidzein 0.04  0.03 0.0157 346 13 0.75  0.15 0.0037 459 17 0.33  0.10 0.0058 290 25
Estradiol 6.40*  4.39 100 288 62 27.67*  9.24 100 351 14 18.77*  1.99 100 414 67
NA, not applicable; *, pM.
a EC25 and EC50 values are test compound concentrations required to achieve 25% and 50%, respectively, of the effect of 0.1 nM estradiol.
Values are mean  SEM of at least three independent experiments.
b Relative potency was calculated by the following: [100  EC25 (or EC50) of estradiol]/[EC25 (or EC50) of test compound].
c All compounds were tested at 10 M. Estradiol was tested at 0.1 nM. Efficacies (% of control, mean SEM of three independent experiments)
indicate absorbance of MTT-formazan in MCF-7 cells (cell proliferation), luciferase activity in MCF-7:D5L cells (reporter gene expression), and
alkaline phosphatase activity in Ishikawa cells.
10.9–12.5 A˚, and hydrophobic centers mimicking steric analogous to the OH of the A-ring of estradiol, geometry
optimizations were performed, allowing 4-OH to interact7 and 11 substituents. Conformational analysis of
1–11 using molecular mechanics calculations [32] re- with Glu305 and Arg346, the 4-OH to interact with
His475 and vice versa, and rotating around the O-Ovealed that each can adopt three low energy conforma-
tions stabilized by the formation of a hydrogen bond
between 2-OH and the carbonyl oxygen (Figure 4A).
Conformers I and III are bended and further stabilized
through the hydrophobic interaction of the phenyl rings,
while conformer II, with a relative energy of 0.5 kcal/
mol compared to the global minimum conformer I, exhib-
its an extended shape comparable to daidzein and geni-
stein. Conformer II of 1–4 and 7–9 has a O-O distance
between the 4 and 4-OH groups of 12.0 A˚, in agreement
with one of the criteria for optimum interaction with ER.
Alignment
To deduce structure-activity relationships, docking cal-
culations were performed and followed by correlation
between the experimental RBA values and the calcu-
lated binding energy Ebind. Since the initial orientation of
the ligand inside the binding pocket is critical, prelimi-
nary calculations were performed to deduce the initial
alignments using the published crystal structure of gen-
istein bound to the LBD of ER [8]. In this structure,
4-OH interacts with the side chains of Glu305, Arg346,
and a buried water molecule mimicking the A-ring of
estradiol, whereas the 7-OH group of the flavone core
is H bonded to His475 at the distal end of the binding
cavity (see Figure 5A). In addition, the keto- and 5-OH
groups are buried toward the -face pocket (roughly the
7 position of estradiol). Deoxybenzoins 1, 3, 5, 6, and
9–11 (lacking a 4-OH) were positioned in the ER-
genistein structure fitting the phenyl ring of genistein
with 4-OH. Energy minimization calculations were per-
Figure 4. Low-Energy Conformers of Deoxybenzoin 2 and ER Bind-
formed by rotating the molecule around the O-O axis ing Affinity Predictions
180 inside the binding pocket. In all cases, in the mini-
(A) The three low energy conformers of 2 as deduced using Monte
mum energy structure the keto- and the 2-OH groups Carlo MM2 conformational search.
were oriented to the -face of the cavity. Since 2, 4, 7, (B) Plot of experimental lnRBAs versus predicted lnRBAs. Triangles
represent the training set, and circles represent the test set.and 8 bear two hydroxyl groups that could play a role
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ing genistein and compound 2 for the test set. The de-
duced correlation between experimental and predicted
lnRBA (Figure 4B) has a total correlation coefficient of
0.932 (r2) with an RMS prediction error of 0.68. Genistein
and 2 were then positioned within the fixed receptor
cavity and “Monte Carlo minimized” to yield a satisfac-
tory correlation between experimental and theoretical
values for the test molecules (Figure 4B), suggesting
that the model is apt to predict relatively high and low
RBA values.
According to the deduced model, genistein, daidzein,
2, 7, and 8 are similarly positioned, and 2, in particular,
superimposes to genistein perfectly (Figure 5A). Daidzein
also superimposes to genistein, but the lack of 5-OH
seems to hamper its ER binding selectivity. As already
reported for genistein [8], the ER binding selectivity of
2 could be due to an interaction with Met336 (Leu384
in ER), one of the two cavity-lining residues that differ
between ER and ER. Met336 and Met340 interact
through a hydrogen bond between backbone NH and
CO, and both lie very close above the keto and the 2-OH
groups of 2 (Figure 5A). The sulfur atom of both residues,
bearing a weak polar character, could interact with these
two groups, thus contributing to the selectivity toward
ER. While 7 and 8 also bind like genistein, they bear a
Cl atom toward a hydrophobic pocket very close to
Val484, the first residue of helix 12, which possibly ex-
plains their lower activity compared to 2. Deoxybenzoins
1, 3–6, and 9–11 are oriented in the cavity in the opposite
direction compared to genistein, with the two aromatic
rings perpendicular to each other, thus deviating from
the planar shape of genistein (Figure 5B). In this orienta-
tion, the 3-Br atom of 11 is found in the same position
like 16-H of estradiol. In estradiol, Br substitution for
16a H is very well tolerated (similar RBA) [35], which is
Figure 5. Comparative Molecular Modeling of Deoxybenzoin Bind- in accordance with the relatively high RBA of 11.
ing of ER In light of the above, it appears that a deoxybenzoin
(A) Superposition of Genistein and 2 in the ER binding site as de- orientation that provides for H bonding of His475 (His
duced using PrGen calculations. Met336 and Met340 lie above and 524 in ER) with 4-OH is necessary for activation of
very close to keto and OH groups of the ligand. cell proliferation as well as gene expression to a level
(B) Superposition of estradiol and 11 in the ER binding site. The
comparable or even higher than that of estradiol (e.g.,position Br atom of 11 is close to the position of 16 substituent
2); that derivatization of 4-OH is more detrimental toof estradiol.
stimulation of cell proliferation than gene expression
(e.g., 1); and that deoxybenzoins lacking a 4 O atom
axis 180. The minimum energy structures thus obtained but possessing appropriate 3 substituents (5, 11) may
were subjected to docking calculations which revealed inhibit or fail to promote cell proliferation while main-
that 2, 7, and 8 prefer to bind similar to genistein, with taining most of the efficacy of 1 and 2 to activate gene
the keto- and 2-OH groups in similar positions to the expression, albeit with reduced potency. On the whole,
corresponding groups of genistein, while 4 adopts a it appears that the proliferative activity of 1–4 and 7–9
similar position to 1, 3, 5, 6, and 9–11. should be correlated with the presence of two O atoms
Scoring being able to meet one of the structural requirements
To produce a model relating calculated energy terms to for estrogenicity. Since 1 and 2 bear two OH atoms at
binding affinities, the molecules were aligned as above, a distance of 12 A˚ and the 4-OH of 1 is methylated, they
positioned in the ER cavity, and subjected to docking- likely contact His475 as H-bond acceptor and donor,
scoring iterative calculations using PrGen 2.0 software. respectively. It has been reported, however, that ligand
Theoretical binding affinities are estimated by evaluating H bonding of an acceptor His475 begins a H-bond net-
ligand-receptor interaction energies, ligand desolvation work that involves Glu371, extends to the C terminal of
energies, and changes in both ligand-internal energy and helix 11, and stabilizes the agonist position of helix 12;
ligand-internal entropy upon receptor binding: Ebinding  and that disruption of this network lowers the gene ex-
Eligand-receptor  TSbinding  Gsolvation,ligand  Einternal,ligand [33]. pression potency and efficacy of ER [34]. However, our
Binding affinities are then obtained by linear regression data suggest that it is deoxybenzoin activation of cell
between lnRBA and Ebinding. A training set of 12 molecules proliferation rather than gene expression that is primarily
affected by disruption of the H-bond network, and thatwas used, including estradiol and daidzein, while keep-
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by NMR (1H-NMR, 13C-NMR, HMBC, HMQC, COSY-LR) and MS-CIone can synthesize ER-selective antiproliferative de-
spectroscopy.oxybenzoins lacking 4-OH, which nevertheless can ef-
2,4-Dihydroxy-4-Nitrodeoxybenzoin [2-(4-Nitrophenyl)-1-fectively activate gene expression (e.g., 11). Van der
(2,4-Dihydroxyphenyl)Ethanone] 6
Waals contacts of appropriate 3 substituents (e.g., Br) 1H NMR (MeOD, 400 MHz) : 8.17 (2H, d, J 	 8.0 Hz, H-3/H-5),
with Ile373 (Met421 in ER) [8], the other cavity-lining 7.85 (1H, d, J 	 8 Hz, H-6), 7.51 (2H, d, J 	 8.0 Hz, H-2/H-6), 6.38
(1H, dd, J 	 8.0/1.5 Hz, H-5), 6.27 (1H, d, J 	 1.5 Hz, H-3), 4.42 (2H,molecule that differs between ER and ER, may be
s, CH2). 13C NMR (MeOD, 50 MHz) : 202.5 (CO), 166.8 (C-4/C-2),instrumental for the maintenance of gene expression
148.5 (C-4),144.2 (C-1), 134.6 (C-6), 132.4 (C-2/C-6), 124.2 (C-3/activity of 11. Thus, it appears that certain deoxyben-
C-5), 114.0 (C-1), 110.0 (C-5), 104.2 (C-3), 46.8 (CH2). MS-CI, m/zzoins can replicate the activity of established selective
274 (MH).
ER modulators (SERMs) such as tamoxifen, and subtle 5-Cloro-2,3,4,4-Tetrahydroxy-Deoxybenzoin [1-(5-Cloro-
structural alterations of the deoxybenzoin scaffold can 2,4-Dihydroxyphenyl)-2-(3,4-Dihydroxyphenyl)Ethanone] 8
1H NMR (Me2CO-d6, 400 MHz) : 7.82, (1H, s, H-6), 6.73 (1H, d, J 	give rise to receptor-ligand complexes of such a topol-
8.0 Hz, H-5), 6.73 (1H, d, J 	 1.5 Hz H-2), 6.60 (2H, dd, J 	 8.0/ogy and interaction with coregulators that could provide
1.5 Hz, H-6), 6.40 (1H, s, H-3), 4.02 (2H, s, CH2). 13C NMR (CDCl3,for the dissociation of the proliferative and gene expres-
50 MHz) :). 204.1 (CO), 165.9 (C-4), 162.3 (C-2), 148.2 (C-3),146.7sion responses of breast cancer cells to estradiol [36].
(C-4), 134.3 (C-6), 128.2.0 (C-1), 123.7 (C-6), 118.3 (C-2),118.3
(C-5), 114.5 (C-5), 114.5 (C-1), 105.7 (C-3), 47.1 (CH2). MS-CI, m/z
Significance 295 (MH).
5-Cloro-2,4-Dihydroxy-4-Ethoxydeoxybenzoin [1-(5-Cloro-
2,4-Dihydroxyphenyl)-2-(4-Ethoxyphenyl)Ethanone] 9While HRT of postmenopausal syndromes is associ-
1H NMR (Me2CO-d6, 400 MHz) : 7.82, (1H, s, H-6), 7.06 (2H, d, J 	ated with a higher risk of developing breast and/or
8.0 Hz, H-2/H-6), 6.78 (2H, d, J 	 8.0 Hz, H-3/H-5), 6.38 (1H, s,
endometrial cancer, consumption of dietary estrogens H-3), 4.02 (2H, s, CH2), 3.91 (2H, q, CH2CH3), 1.32 (3H, t, CH3). 13C
is thought to have the opposite effect [1, 2]. However, NMR (CDCl3, 50 MHz) : 203.9 (CO), 164.0 (C-4), 162.1 (C-2), 159.9
the exact mechanisms underlying the complex estro- (C-4), 134.3 (C-6), 132.0 (C-2/C-6), 127.9 (C-1), 116.3 (C-3/C-5),
113.9 (C-1), 113.9 (C-5), 105.2 (C-3), 64.3 (CH2CH3), 44.9 (CH2), 15.8genic/antiestrogenic behavior of most phytoestro-
(CH2CH3). MS-CI, m/z 307 (MH).gens remain a matter of conjecture. It is believed that
4-Bromo-2,4-Dihydroxydeoxybenzoin [2-(4-Bromophenyl)-the beneficial effects associated with consumption of
1-(2,4-Dihydroxyphenyl)Ethanone] 10
phytoestrogens reflect their preferential activation of 1H NMR (MeOD, 400 MHz) : 7.79 (1H, d, J 	 8 Hz, H-6), 7.42 (2H,
ER function(s) [5]. The present report shows that d, J 	 8.0 Hz, H-3/H-5), 7.14 (2H, d, J 	 8.0 Hz, H-2/H-6), 6.37
0.1–3 M 2 can effectively compete with postmeno- (1H, dd, J 	 8.0/1.5 Hz, H-5), 6.27 (1H, d, J 	 1.5 Hz, H-3), 4.13 (2H,
s, CH2). 13C NMR (MeOD, 50 MHz) : 203.7 (CO), 167.0 (C-4/C-2),pausal estrogen for binding to the native ER and that
135.8 (C-1),134.6 (C-6), 133.0 (C-2/C-6), 133.0 (C-3/C-5), 121.7the ER binding selectivity and transcriptional bias of
(C-4), 113.9 (C-1), 108.9 (C-5), 104.3 (C-3), 45.7 (CH2). MS-CI, m/z2 is accompanied by higher activation of transcription
308 (MH).
of estrogen target genes compared to estradiol, which 3-Bromo-2,4-Dihydroxydeoxybenzoin [2-(3-Bromophenyl)-
makes 2 potentially useful for HRT. It is known, how- 1-(2,4-Dihydroxyphenyl)Ethanone] 11
ever, that the proliferation of breast cancer cells is 1H NMR (MeOD, 400 MHz) : 7.79 (1H, d, J 	 8 Hz, H-6), 7.47 (1H,
t, J 	 1.5 Hz, H-2), 7.40 (2H, dt, 7.14 J 	 8.0/1.5 Hz, H-4), 7.27-driven predominantly by ER, the number of ER-posi-
7.16 (2H, m, H-5/H-6), 6.37 (1H, dd, J 	 8.0/1.5 Hz, H-5), 6.27 (1H,tive proliferating cells of the human breast increases
d, J 	 1.5 Hz, H-3), 4.13 (2H, s, CH2). 13C NMR (MeOD, 50 MHz) :with advancing age [37], and that, while the level of
210.6 (CO), 167.3 (C-4), 167.2 (C-2), 139.5 (C-1),134.7 (C-6), 134.1
ER decreases in preinvasive mammary tumors, that (C-2), 131.8 (C-4), 131.8 (C-4), 131.4 (C-6), 130.0 (C-5), 113.9
of ER increases instead [38]. In this light, a HRT based (C-1), 109.8 (C-5), 104.2 (C-3), 45.3 (CH2). MS-CI, m/z 308 (MH).
on 2 could increase breast cancer risk. Interestingly, Daidzein, 7-Hydroxy-3-(4-Hydroxyphenyl)-Chromen-4-One
In a solution of 2 (2 mmol) in DMF (6 ml), freshly distilled BF3·Et2Ofrom the subset of ER-selective and transcriptionally
(6.3 ml) was added under argon. The mixture was heated at 50C,competent deoxybenzoins lacking a 4-OH, one (11)
and a solution of methanesulphonyl chloride (1 ml) in dry DMF (1.5can activate gene expression and inhibit cell prolifera-
ml) was added slowly. After reaction at 80C for 1 hr, the mixturetion at the same time. Such deoxybenzoins are a po-
was cooled to room temperature and poured into a large volume
tentially safe choice for HRT, especially if their RBA of ice-cold aq. sodium acetate (12 g/100 ml), then extracted with
were to improve while their selectivity and transcrip- ethyl acetate, and the organic layer was dried and concentrated. The
tional bias toward ER is maintained compared to 11. residue was purified by column chromatography on silica gel using a
mixture of dichloromethane and methanol. For 1H NMR, see [39].
Experimental Procedures
ER Binding AffinitiesNMR spectra were recorded on Bruker DRX 400 and Bruker AC 200
These were determined using a fluorescent ER ligand (ES2) andspectrometers [1H (400 and 200 MHz) and 13C (50 MHz)]; chemical
recombinant ERor ERwith a Beacon 2000 Fluorescence Polariza-shifts are expressed in ppm downfield from TMS. The 1H-1H and the
1H-13C NMR experiments were performed using standard Bruker tion (FP) System (PanVera) as described by Bolger et al. [17]. Test
microprograms. compound competition of 1 nM ES2 binding to ER obeys the follow-
ing scheme: Test  ER-ES2 (high FP) → ER-Test  ES2 (low FP).
IC50 values for estradiol thus determined using ER and ER werePreparation of Deoxybenzoins
1.24 0.07 and 1.45 0.18 nM, respectively. Deoxybenzoin compe-A phenol (0.050 mol) and an arylacetic acid (0.050 mol) were dis-
tition of ES2 binding to ER gave IC50 estimates from which RBAsolved into freshly distilled BF3·Et2O under argon. The mixture was
values were calculated by [(IC50 estradiol/IC50 competitor)  100].stirred at 80C and then poured in an ice bath. The resulting mixture
FP values for ER-bound ES2 in the absence of competitor and ofwas extracted with ethyl acetate, and the organic layer was washed
both ER and competitor served as negative and positive displace-with aq. NaHCO3, dried (Na2SO4), and evaporated. The residue was
ment controls, respectively. ES2 displacements were curve fittedpurified by column chromatography on silica gel, using a mixture
of dichloromethane and methanol. All compounds were identified using SigmaPlot 4.0 (SPSS Inc).
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Stimulation of Cell Proliferation (initial dilution in DMSO, further dilutions in culture medium). Cells
were cultured for 72 hr. To assay AlkP activity [30, 31], the cellsMCF-7 and MDA-MB-231 human mammary adenocarcinoma cells
were washed with PBS, the plates were inverted, blotted gently on(ATCC, Rockville, MD) were cultured at 37C in Dulbecco’s minimal
a paper towel, placed at 80C for at least 15 min, thawed at roomessential medium (DMEM) supplemented with 10% fetal bovine se-
temperature for 5–10 min, and then transferred on ice. Next, 50 lrum (Biochrom KG, Berlin) in 5% CO2 and subcultured using a trypsin
ice-cold solution containing 5 mM p-nitrophenyl phosphate, 0.240.25%–EDTA 0.02% solution. To assess cell proliferation, a modifi-
mM MgCl2, and 1 M diethanolamine (pH 9.8) was added, the cellscation of the MTT assay was used [40]. Briefly, cells were plated in
were warmed to room temperature (time zero), and yellow-colored96-well flat-bottomed microplates at a density of 10,000 cells/well
p-nitrophenol was allowed to accumulate. Cells that received onlyin phenol-red-free medium supplemented with 1% dextran-coated-
medium served as negative controls, while cultures treated with 0.1charcoal-pretreated FBS (DCC-FBS) [41]. Twenty-four hours later,
nM estradiol served as positive controls. The color was monitoredserial dilutions of test compounds were added (initial dilution in
every 30 min at 405 nm using the Galaxy 1258 plate reader untilDMSO, further dilutions in culture medium), fresh media with test
positive controls showed an absorbance (A405) of about 1.2.compounds was added every 48 hr, and after 6 days the medium
was removed and the cells were incubated with 1 mg/ml MTT [3-(4,5-
Molecular Modelingdimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma, St.
The calculations were performed using the crystal structure ofLouis, MO) in serum-free, phenol-red-free medium for 4 hr. The MTT-
ER-LBD with genistein, taking into account all of the amino acidsformazan produced was solubilized in isopropanol, and absorbance
within 12 A˚ from the ligand and the crystallographic water moleculeat 550 nm versus 690 nm was measured. Cells that received only
among genistein, GLU305, and ARG346. The structure includes resi-medium served as baseline controls, while those treated with estra-
dues from the adjacent subunit, some of which are known to affectdiol (Sigma) served as positive controls. The difference in the re-
binding [8]. His475 was protonated in nitrogen N2.sponses of MCF-7 and MDA-MB-231 cells was taken to measure
The 14 ligand molecules (training and test set) were designed andestrogenic activity.
energy minimized (MM2) using MACROMODEL 6.5 software [32].
The full search in the conformational space was achieved using
Transactivation of Reporter Gene Expression MM2 force field-Monte Carlo multiple minimum method (MCMM) as
HEK-293 cells were maintained and transfected as described by Pet- implemented in MACROMODEL 6.5. One thousand starting con-
tersson et al. [28], with minor modifications. In brief, cells were seeded formers were produced and minimized using the TNCG algorithm
in 6 cm dishes and transfected with the calcium phosphate coprecipita- (rmsG  0.01 kJ/mol·A˚). For the preliminary minimizations of all
tion method using 1.5 g of pERE-tk-Luc reporter plasmid, 1 g of ligands inside the binding pocket, the AMBER* united atom force
internal control plasmid pCMX-Gal, 0.1 g of pSG5-hER or pGS5- field was used with a distance-dependent dielectric “constant” of
hER expression plasmids alone, or 0.1 g of pSG5-hER together 4r as implemented in MACROMODEL 6.5. All calculations with MAC-
with 0.1 or 0.2 g of pSG5-hER, as indicated. Sixteen to eighteen ROMODEL 6.5 software were run on a Silicon Graphics O2 R5000.
hours after transfection, cells were washed with phosphate buffered For lnRBA prediction, the PrGen 2.0 program was used. At the
saline (PBS) and incubated in fresh medium with or without 1 nM beginning, the crystal structure of ER-LBD with genistein was mini-
estradiol, the indicated deoxybenzoin concentrations, or vehicle mized over 100 steps using PrGen. All molecules were then superim-
(0.1% DMSO) for 24 hr. Luciferase activities were normalized relative posed over the crystallographic position of genistein as described.
to -galactosidase expression levels. Plasmids pERE-tk-Luc, pSG5- Partial atomic charges were attributed using MOPAC 7 (MNDO ham-
hER, and pSG5-hER have been described [26]. iltonian with NOMM correction) [42]. Solvation energies, entropy
MCF-7 cells were transfected with the luciferase reporter plasmid corrections, and ligand reference energies were calculated for all
ERE- Glob-Luc [27] and neomycin resistance plasmid pWL2neo ligands after individual Monte Carlo minimization using specific
(Stratagene) using standard methodology. Transfectants were se- built-in PrGen 2.0 modules. To determine ligand-receptor interaction
lected using geneticin (Stratagene). The geneticin-resistant clone energy, Eligand-receptor, the program uses the force field Yeti [43]. Binding
D5L of MCF-7 cells, selected for its prominent induction of reporter affinities are obtained by linear regression between lnRBA and Ebinding.
expression by estradiol and low basal expression in its absence, as All calculations with PrGen 2.0 were run on a Silicon Graphics INDY
R4500.assessed using the Steady-Glo Luciferase Assay System (Promega),
was cultured as described above for MCF-7 cells. To assess lucifer-
Statisticsase induction by deoxybenzoins, MCF-7:D5L cells were plated in
Data were analyzed using the SPSS 10.0 statistical package for96-well flat-bottomed microplates at a density of 10,000 cells/well
Windows and compared using one-way ANOVA with a Tukey Postin phenol-red-free MEM supplemented with 5% DCC-FBS; 72 hr
Hoc test for multiple comparisons. Differences were consideredlater, fresh medium was added to the cells followed by test com-
statistically significant for values of p 0.05. The Pearson’s correla-pounds (initial dilution in DMSO, further dilutions in culture medium).
tion coefficient (r) was used to analyze statistical associations.Luciferase activity was assayed 16 hr later using a Galaxy 1258
plate reader (BioOrbit). Cells that received only medium served as
Acknowledgmentsbaseline expression controls.
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